The need for improved treatments of IDDM remains unmet due to the potential drawbacks of insulin therapy, including an increased risk of life-threatening hypoglycemia and weight gain, which are associated with insulin resistance and cardiovascular events [47]. The gene discussed is INS; the disease is type 1 diabetes mellitus.